EA201491643A1 - Идентификация мутаций канал-опсина-2 (chop2) и способы применения - Google Patents

Идентификация мутаций канал-опсина-2 (chop2) и способы применения

Info

Publication number
EA201491643A1
EA201491643A1 EA201491643A EA201491643A EA201491643A1 EA 201491643 A1 EA201491643 A1 EA 201491643A1 EA 201491643 A EA201491643 A EA 201491643A EA 201491643 A EA201491643 A EA 201491643A EA 201491643 A1 EA201491643 A1 EA 201491643A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chop2
opsin
canal
mutations
identification
Prior art date
Application number
EA201491643A
Other languages
English (en)
Russian (ru)
Inventor
Чжо-хуа Пань
Original Assignee
Уэйн Стейт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уэйн Стейт Юниверсити filed Critical Уэйн Стейт Юниверсити
Publication of EA201491643A1 publication Critical patent/EA201491643A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201491643A 2012-03-05 2013-03-05 Идентификация мутаций канал-опсина-2 (chop2) и способы применения EA201491643A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Publications (1)

Publication Number Publication Date
EA201491643A1 true EA201491643A1 (ru) 2015-02-27

Family

ID=47892055

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491643A EA201491643A1 (ru) 2012-03-05 2013-03-05 Идентификация мутаций канал-опсина-2 (chop2) и способы применения

Country Status (16)

Country Link
US (3) US10947281B2 (https=)
EP (1) EP2822964B1 (https=)
JP (3) JP6395611B2 (https=)
KR (1) KR102137717B1 (https=)
CN (2) CN104334575A (https=)
AU (4) AU2013230112A1 (https=)
CA (1) CA2866405A1 (https=)
DK (1) DK2822964T3 (https=)
EA (1) EA201491643A1 (https=)
ES (1) ES2703324T3 (https=)
HU (1) HUE040487T2 (https=)
MX (1) MX360085B (https=)
NZ (1) NZ629843A (https=)
PL (1) PL2822964T3 (https=)
PT (1) PT2822964T (https=)
WO (1) WO2013134295A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
AU2013230112A1 (en) 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
US9730888B2 (en) 2013-03-14 2017-08-15 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
JP6469669B2 (ja) 2013-07-08 2019-02-13 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se オキシムエステル光開始剤
AU2015229464B2 (en) 2014-03-11 2021-07-22 Wayne State University A modified mGluR6 promoter and methods of use
RU2018142273A (ru) 2016-05-03 2020-06-03 Чжо-хуа Пань Способ улучшения опосредованной вирусами доставки генов в глаз с использованием ингибиторов протеасом
WO2017207745A1 (en) * 2016-06-03 2017-12-07 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Mutant light-inducible ion channel of channelrhodopsin
CA3034887A1 (en) * 2016-08-29 2018-03-08 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
EP3609518A1 (en) * 2017-04-12 2020-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
SI3720428T1 (sl) * 2017-12-04 2023-05-31 Laboratorios Salvat, S. A. Oftalmični lokalni sestavek, ki vsebuje dobesilno kislino za zdravljenje bolezni posteriornega očesnega segmenta
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
CA2287495A1 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
JP2007527738A (ja) 2003-11-05 2007-10-04 ニューロヴィジョン, インコーポレイテッド 視覚を改善するための方法および装置
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2011140279A1 (en) * 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
PL2614079T3 (pl) * 2010-09-08 2016-01-29 Max Planck Gesellschaft Zmutowana kanałowa rodopsyna 2
AU2013230112A1 (en) * 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
AU2019216638B2 (en) 2021-07-08
PL2822964T3 (pl) 2019-05-31
AU2017239601A1 (en) 2017-10-26
AU2021245195B2 (en) 2023-09-28
US20250066431A1 (en) 2025-02-27
HUE040487T2 (hu) 2019-03-28
HK1205744A1 (en) 2015-12-24
CN111378020A (zh) 2020-07-07
US10947281B2 (en) 2021-03-16
AU2013230112A1 (en) 2014-09-25
WO2013134295A1 (en) 2013-09-12
CN104334575A (zh) 2015-02-04
AU2021245195A1 (en) 2021-11-04
MX2014010664A (es) 2015-03-06
MX360085B (es) 2018-10-10
NZ629843A (en) 2017-03-31
NZ727041A (en) 2022-01-28
JP6395611B2 (ja) 2018-09-26
AU2017239601B2 (en) 2019-05-16
CA2866405A1 (en) 2013-09-12
KR102137717B1 (ko) 2020-07-27
EP2822964B1 (en) 2018-08-22
KR20140132401A (ko) 2014-11-17
JP2018134098A (ja) 2018-08-30
JP2019193656A (ja) 2019-11-07
AU2019216638A1 (en) 2019-09-05
ES2703324T3 (es) 2019-03-08
JP2015510759A (ja) 2015-04-13
US20150044181A1 (en) 2015-02-12
EP2822964A1 (en) 2015-01-14
PT2822964T (pt) 2018-11-29
US20220033449A1 (en) 2022-02-03
DK2822964T3 (en) 2018-12-10

Similar Documents

Publication Publication Date Title
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
MX385926B (es) Proteínas de fusión de citoquinas.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112014018679A2 (pt) variantes de albumina
MX383537B (es) Mutantes de proteína f de rsv.
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA201691111A1 (ru) Химерные белки фактора viii и их применение
MX374682B (es) Moléculas de unión a 4-1bb.
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
EA201171220A1 (ru) Мутанты fgf21 и их применение
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
MX2017016610A (es) Metodos de reduccion de olor.
EA201590845A1 (ru) Варианты fc-гамма-рецептора iib
NZ751983A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
EA201591421A1 (ru) Препараты полипептида фактора ix
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins